Among the 75 patients with HER2+ breast cancer, 33 (44.0%) received neoadjuvant chemotherapy plus trastuzumab, while 42 (56.0%) received neoadjuvant chemotherapy plus trastuzumab and pertuzumab (Table 1). This evidence concerns the gene ERBB2 and breast cancer.